BridgeMD
(NFPET) 89Zr-Bevacizumab PET/CT imaging in NF2 patients
EU CTIS ID: 2024-512860-75-00
What this study is testing
To validate pre-treatment [89Zr]-bevacizumab PET/CT as an imaging biomarker for prediction of a hearing response to bevacizumab treatment in patients with NF2 related (vestibular) schwannomas.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients aged 18 years or older
- Confirmed diagnosis of NF2 by revised Manchester criteria (appendix C)
- Provided written informed consent
- Patients must have measurable disease, defined as at least one VS > 0.4 ml (on volumetric analysis) that can be accurately measured by contrast-enhanced T1- weighted cranial MRI scan
- Eligible and planned for bevacizumab treatment
You likely can't join if
- Patients with a contra-indication for PET and MRI, such as pregnancy and metal elements.
- Patients with a known allergy to substances used in this study
- Concurrent treatment with Everolimus
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.